For example, CD25 (targeted by mAb22) has been proposed as a target molecule for Treg depletion31,32, and ox40 (mAb23) a target for augmenting anti-tumor immune responses by activating effector T-cells33–35. Here, TNFRSF4 is linked to neoplasm.